Effect of Sitafloxacin and Amikacin Liposome Inhalation Suspension on Clarithromycin-Resistant Pulmonary Mycobacterium avium Complex Disease: A Case Series

Clarithromycin (CAM)-resistant pulmonary <i>Mycobacterium avium</i> complex (MAC) disease poses significant treatment challenges. This case series describes four patients treated with sitafloxacin (STFX) and amikacin liposome inhalation suspension (ALIS) in addition to standard guideline-based therapy (GBT). Sputum culture negativity was achieved in two patients, both under 65 years old and without cavitary lesions. These findings suggest the potential efficacy of STFX and ALIS as adjuncts to GBT for CAM-resistant pulmonary MAC disease, particularly in younger patients with non-cavitary disease.